Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance
Open Access
- 31 August 1988
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 58 (3) , 335-340
- https://doi.org/10.1038/bjc.1988.214
Abstract
The role of the calmodulin inhibitor trifluoperazine (TFP) in modulating the cellular levels and cytotoxicity in vitro and antitumour effects in vivo of doxorubicin (DOX), was evaluated in progressively DOX-resistant (5- to 40-fold) sublines of B16-BL6 mouse melanoma. In parental-sensitive B16-BL6 cells treated for 3 h, the IC50 of DOX was 0.1 microgram ml-1, and a less than 2-fold enhancement in DOX cell kill in the presence of a noncytotoxic concentration of 5 microM TFP was observed. However, in the DOX-resistant sublines, the IC50 was 0.7 to 5.0 micrograms ml-1 DOX in the absence of 5 microM TFP and 0.3 to 0.7 microgram ml-1 DOX in the presence of 5 microM TFP. The 2- to 7.5-fold decrease in the IC50 of DOX in the presence of 5 microM TFP, was dependent on the level of DOX-resistance in the various sublines. Compared to parental-sensitive cells, a 2-fold decrease in DOX-accumulation was evident only in the 40-fold DOX-resistant subline. Further, maximal enhancement (50%) of cellular DOX accumulation in the presence of 5 microM TFP was observed only in the 40-fold resistant cells treated with 5.0 micrograms ml-1 DOX. Retention of DOX in the 40-fold resistant subline was only 20% lower than similarly treated sensitive cells, and the inclusion of TFP increased DOX retention less than 10-15%. Antitumour studies in mice with experimental pulmonary metastases revealed that although DOX and DOX plus TFP had similar antitumour activity with the parental sensitive B16-BL6 cells, the combination of DOX plus TFP was significantly more effective than DOX alone with the DOX-resistant sublines. No overt toxicity was observed in normal mice treated with doses of TFP, DOX or DOX plus TFP used for in vivo chemotherapy studies. Results from this study suggest that gross cellular DOX levels do not appear to correlate with the magnitude of resistance, and the effects of TFP in modulating DOX resistance is possibly due to mechanisms other than mere alterations in cellular drug accumulation and/or retention.Keywords
This publication has 21 references indexed in Scilit:
- Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cellsBiochemical Pharmacology, 1988
- Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistanceNature, 1986
- VERAPAMIL-MEDIATED SENSITIZATION OF DOXORUBICIN-SELECTED PLEIOTROPIC RESISTANCE IN HUMAN SARCOMA-CELLS - SELECTIVITY FOR DRUGS WHICH PRODUCE DNA SCISSION1986
- Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong VS weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cellsBiochemical and Biophysical Research Communications, 1985
- ANTHRACYCLINE RESISTANCE IN P388 MURINE LEUKEMIA AND ITS CIRCUMVENTION BY CALCIUM-ANTAGONISTS1985
- Genetic and biochemical characterization of multidrug resistancePharmacology & Therapeutics, 1985
- Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of Doxorubicin (Adriamycin) in resistant P388 mouse leukemia cellsEuropean Journal of Cancer and Clinical Oncology, 1984
- Comparison of anthracycline concentrations in S180 cell lines of varying sensitivityEuropean Journal of Cancer and Clinical Oncology, 1983
- ENHANCEMENT OF SENSITIVITY TO ADRIAMYCIN IN RESISTANT P388-LEUKEMIA BY THE CALMODULIN INHIBITOR TRIFLUOPERAZINE1983
- Verapamil Restoration of Daunorubicin Responsiveness in Daunorubicin-resistant Ehrlich Ascites CarcinomaJournal of Clinical Investigation, 1982